Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827592 · ClinicalTrials.gov registry record · Phase 3
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
NCT01827592: Clinical Trial Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT01827592 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 376 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01827592, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
Study Summary
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
Primary Outcome
This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.
Interventions
- DRUG Placebo
- DRUG Elobixibat 10 mg
- DRUG Elobixibat 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Why NCT01827592 stopped before completion
NCT01827592 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01827592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01827592 about?
NCT01827592 is a clinical study titled "26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation". Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
What is the current status of trial NCT01827592?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01827592?
The interventions under investigation include: Placebo (DRUG), Elobixibat 10 mg (DRUG), Elobixibat 5 mg (DRUG).
Who is sponsoring clinical trial NCT01827592?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01827592's enrollment target sits among peer trials
376 988th of 2000 higher than 1,013 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia